The LYCRA Company Launches LYCRA EnviroFit™ Fiber at INDEX™ 23
13.4.2023 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the personal care and apparel industries, is exhibiting its newest fiber innovations for hygiene and personal care products at INDEX™ 23, the world’s leading nonwovens exhibition, which takes place at Palexpo in Geneva, Switzerland, April 18 – 21.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005005/en/
The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber for personal care products at INDEX™ 23, April 18 – 21. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping to conserve resources without compromising product performance. (Photo: Business Wire)
At the trade show, The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber, one of the many fibers that the company has developed as part of its Planet Agenda sustainability platform. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping conserve resources without compromising product performance.
“We are thrilled to introduce LYCRA EnviroFit™ fiber, which reduces fiber weight while maintaining the overall quality and performance that personal care products require,” said Scott Blackadar, president, personal care at The LYCRA Company. “Having less mass means fewer resources and less energy are consumed during diaper production. This fiber will appeal to manufacturers who want to significantly reduce their product’s environmental impact and help improve its carbon footprint.”
In addition to continuously improving its range of fibers for personal care products, The LYCRA Company also focuses on providing total solutions for the challenges its customers face. The company is offering two unique delivery technologies aimed at improving the spandex unwinding process and improving diaper line productivity that will also be promoted at the show.
Introducing Trio Loop Yarn Control
The LYCRA Company is showcasing the Trio Loop Technology at INDEX™ 23, the latest yarn control system from BTSR International S.p.A. Trio Loop Technology, in combination with MATRIXCUBE tension controlled plug-and-play unwinding systems, improves yarn tension control and adds more troubleshooting options to further improve diaper line productivity.
Distributing Knotter Type 093E
The LYCRA Company is also the exclusive global distributor of the new and improved Knotter Type 093E for diaper production. This breakthrough innovation by Mesdan S.p.A. offers manufacturers greater efficiency and reliability by eliminating manual knot tying and reducing machine stops.
“By offering these delivery technologies, we are demonstrating that we are a trusted and highly valued solution provider in the industry,” said Werner Hopstaken, global director, personal care at The LYCRA Company. “We are excited to offer our personal care customers these innovative products by BTSR and Mesdan and encourage them to contact us to learn more.”
Visit The LYCRA Company representatives at INDEX™ 23 stand number 2151 or visit this website to discover more benefits of these innovations.
About INDEX™ 23
INDEX™ 23 is the largest global trade show for the nonwovens market. Held every three years, it attracts thousands of visitors from over 100 countries in every region. In addition to its exhibit space, INDEX™ hosts free industry workshops, seminars, tutorials, and presentations during the show. For more information, visit indexnonwovens.com.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, marketing support, and LYCRA ONE™ marketplace. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
LYCRA EnviroFit™ is a trademark of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005005/en/
Contact information
Werner Hopstaken
werner.hopstaken@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom